Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $227000.0.

  • Maxcyte's Other Non-Current Liabilities fell 1805.05% to $227000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $227000.0, marking a year-over-year decrease of 1805.05%. This contributed to the annual value of $274000.0 for FY2024, which is 318.02% down from last year.
  • As of Q3 2025, Maxcyte's Other Non-Current Liabilities stood at $227000.0, which was down 1805.05% from $248000.0 recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Other Non-Current Liabilities ranged from a high of $1.3 million in Q4 2022 and a low of $227000.0 during Q3 2025
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $393000.0 (2022), whereas its average is $611747.1.
  • Per our database at Business Quant, Maxcyte's Other Non-Current Liabilities surged by 23292.62% in 2023 and then tumbled by 7898.97% in 2024.
  • Over the past 5 years, Maxcyte's Other Non-Current Liabilities (Quarter) stood at $450200.0 in 2021, then soared by 193.2% to $1.3 million in 2022, then tumbled by 78.56% to $283000.0 in 2023, then fell by 3.18% to $274000.0 in 2024, then decreased by 17.15% to $227000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $227000.0 for Q3 2025, versus $248000.0 for Q2 2025 and $270000.0 for Q1 2025.